Marine Compounds and Cancer 2020

The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the las...

Descrición completa

Gardado en:

Detalles Bibliográficos
Formato:	Online
Idioma:	inglés
Publicado:	MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:	apoptosis fucoidan hepatocellular carcinoma reactive oxygen species 3-alkylpyridinium polymers nicotine nicotinic acetylcholine receptor non-small cell lung carcinoma melanoma sinulariolide proteomic mitochondria caspase cascade marine fungus sediment anthranilic acid Penicillium paneum cytotoxicity dibromotyrosine mitochondrial dysfunction oxidative stress topoisomerase epigonal organ bonnethead shark Jurkat tumor cell line hippuristanol PEL AP-1 STAT3 Akt colorectal cancer marine mollusc brominated indoles shrimp chemoprevention fatty acids carotenoids cancer nanoparticle osteosarcoma lung metastasis elisidepsin lipid rafts hydroxylated lipids fatty acid 2-hydroxylase cooperative binding membrane permeabilization marine organisms polysaccharides anticancer anticarcinogenic mechanisms of action fumigaclavine C anti-proliferation mitochondrial pathway anti-cancer anti-proliferative carotenoid cell cycle arrest fucoxanthin azoxymethane bioactive natural product isatin in vivo model Marthasterias glacialis L. palmitic acid ER-stress CHOP Antibody Drug Conjugates (ADCs) marine antitumor agents clinical trials approved antitumor agents AD0157 angiogenesis marine drug pyrrolidinedione secondary metabolites cancer preventive chemopreventive trabectedin plitidepsin tumor-associated macrophages tumor microenvironment preclinical anticancer immunity antiangiogenesis fascaplysin cyclin-dependent kinase small cell lung cancer camptothecin poly(ADP-ribose)-polymerase inhibitor breast cancer seaweed therapeutic compounds autophagy marine drugs autophagy inhibitors autophagy inducers macrolide programmed cell death energy stress araguspongine C c-Met HER2 gemcitabine pazopanib phase I safety soft tissue sarcoma pachastrissamine jaspine B carbocyclic analogue sphingosine kinase inhibitor molecular modeling ET-743 DNA minor groove binder chemotherapy bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane (BDDPM) anti-metastatic activity cell adhesion β1-integrin FAK BEL-7402 cell triterpene glycosides sea cucumbers antitumor activities arrest of cell cycle antibacterial marangucyclines deep-sea Streptomyces sp. SCSIO 11594 LS-1 SNU-C5/5-FU TGF-β signaling carcinoembryonic antigen kalkitoxin Moorea producens mitochondria toxin VEGF angiogenesis inhibitor hypoxia-inducible factor-1 HIF-1 Lyngbya majuscula marine metabolites SZ-685C nonfunctioning pituitary adenomas Ecklonia cava phlorotannins dieckol migration sipholenol A ABC transporter multidrug resistance P-gp/ABCB1 BCRP/ABCG2 MRP1/ABCC1 marine natural products glioblastoma xyloketal B proliferation TRPM7 marine compound ribosomal protein genes snoRNA FAU RPS30 SNORA62 evolution Porifera n/a Penicillium brevicompactum Brevianamide Mycochromenic acid derivative antifouling Caribbean sponge plakortide endoperoxide leukemia multi-drug resistant leukemia Sarcophyton ehrenbergi soft coral terpenes cembranoids cytotoxic activity molecular docking uveal melanoma virtual screening Topo I inhibitor low toxic natural product Ulva fasciata selenium-containing polysaccharide-protein complex pseudopterosin NF-κB p65 inflammation cytokine release IL-6 TNFα MCP-1 glucocorticoid receptor paulomycins Micromonospora antitumor Cantabrian Sea-derived actinobacteria puupehenones sponges antiangiogenic antitumoral porifera/sponge cancer genes molecular oncology bromophenol molecular mechanisms cell cycle PI3K/Akt p38/ERK ROS human lung cancer glycosaminoglycans antiproliferative heparan sulphate gliotoxin NSCLC adriamycin resistance Sepia ink polysaccharides antitumour chemosensitization anticoagulation sea anemone drug discovery endothelial cells RGD motif kunitz type inhibitor prostate cancer antioxidant natural marine compounds marine biotechnology microalgae marine sponges Aeroplysinin Isofistularin pheochromocytoma and paraganglioma metastasis cancer progression cell adhesion molecules integrin β1 hypoxia phycocyanin non-small cell lung cancer NF-κB signaling marine-derived drugs bioanalysis chromatography manzamine A epithelial–mesenchymal transition lung cancer circulating tumor cells signal transduction cisplatin Lampetra morii buccal gland cystatin F anti-angiogenesis cystatin superfamily Antimicrobial peptide (AMP) Tilapia piscidin 4 (TP4) non-small cell lung cancer (NSCLC) itampolin A FBDD p38α novel inhibitor tetracenomycin X cyclin D1 proteasomal degradation p38 c-JUN λ-carrageenan heparanase anticoagulant depolymerisation cell migration Aspergillus naphthopyrones endophytic fungus Leathesia nana mangrove-derived actinomycete ansamycins divergolides apoptosis-inducing activity actinomycin EMT invasion low molecular weight fucoidan extract N-Ras neuroblastoma-rat sarcoma Cancer programmed cell death-ligand 1 programmed cell death-ligand 2 human sarcoma cell line (HT1080 cells) human normal diploid fibroblast (TIG-1 cells) chimera chemical conjugation anticancer agent hybridization α9-nicotinic acetylcholine receptors (nAChRs) breast cancer cells αO-conotoxin GeXIVA targeted therapy gorgonian Leptogorgia humulane sesquiterpenoids anticancer activity 12-deacetyl-12-epi-scalaradial HeLa cells Nur77 MAPK/ERK pathway Mycalin A C15 acetogenins synthetic analogues antiproliferative activity A375 and HeLa cell lines polyoxygenated steroids sponge Haliclona gracilis Thalassia testudinum thalassiolin B polyphenols CYP1A1 benzo[a]pyrene JNK1/2 natural products synergism A549 cells cytoskeleton P2X7 receptor pollution anti-angiogenic gene expression HSP90 inhibitor thema EDItEUR::M Medicine and Nursing
Acceso en liña:	ONIX_20220111_9783036506302_154
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Descripción
Summary:	The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.

Marine Compounds and Cancer 2020

Títulos similares